Insulin Market in the US and Europe 2016-2020


#717642

95pages

Technavio

$ 2500

In Stock

About Insulin

Beta cells of the pancreas produce insulin, a hormone that regulates blood glucose levels, by stimulating cells to absorb glucose from the blood. In the cells, glucose is converted into energy, which is used by tissues and muscles to perform their physiological functions. This process is restricted in people with diabetes, resulting in the accumulation of glucose in the blood. This condition is known as hyperglycemia; it damages body tissues over a period, leading to life-threatening health complications such as diabetic retinopathy and diabetic nephropathy. In type 1 diabetes or gestational diabetes, the immune system attacks the pancreatic cells, resulting in little or no insulin production. In type 2 diabetes, the body does not produce sufficient insulin to regulate blood glucose levels. In both type 1 and type 2 diabetes, the individual requires daily doses of insulin along with other medications, depending on the condition. Different types of insulin products, such as human insulin and insulin analogs, are available for insulin replacement therapy.

Technavios analysts forecast the insulin market in the US and Europe to grow at a CAGR of 6.17% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the insulin market in the US and Europe for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:
US
Europe

Technavio's report, Insulin Market in the US and Europe 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Sanofi
Novo Nordisk
Eli Lilly
Other prominent vendors
Adocia
Biocon
Biodel
Biogenomics
Boehringer Ingelheim
Dance Biopharm
Diasome Pharmaceuticals
Exsulin
Generex
Lexicon Pharmaceuticals
Ligand Pharmaceuticals
MannKind
Macrogenics
Merck
Melior Pharmaceuticals
Metabolic Solutions Development Company
NGM Biopharmaceuticals
NuSirt Biopharma
Oramed Pharmceuticals
PhaseBio Pharmaceuticals
Pfizer
Thermalin Diabetes
Tolerion
VeroScience
vTv Therapeutics
Wockhardt
XOMA

Market driver
Advances in insulin delivery technology
For a full, detailed list, view our report

Market challenge
Complexity of insulin production
For a full, detailed list, view our report

Market trend
Increasing price of insulin drugs
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Assumptions:
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Major branded drug profiles
Actrapid
Apidra
Humalog
Insuman
Lantus
Levemir
NovoMix
NovoRapid
Toujeo
Tresiba
PART 06: Insulin: An overview
History of insulin
Epidemiology
Reimbursement scenario
Patent scenario for approved products
PART 07: Pipeline portfolio
Xultophy (NN9068)
Faster-acting insulin aspart (NN1218)
SAR342434
LY2605541
MK-1293
Oral-Lyn
PART 08: Oral insulin therapies
Upcoming vendors for oral insulin therapies
Oramed Pharmaceuticals
Generex Biotechnology
PART 09: Market landscape
Global insulin market
Insulin market in US and Europe
Market size and forecast
Five forces analysis
PART 10: Market segmentation by drug class
Fast-acting insulin
Intermediate-acting insulin
Long-acting insulin
PART 11: Market segmentation by application
Type 1 diabetes
Type 2 diabetes
PART 12: Market segmentation by insulin delivery technologies
Injectable insulin
Oral insulin
Inhaled insulin
Other emerging insulin delivery technologies
Insulin pumps
PART 13: Geographical segmentation
Insulin market in US
Insulin market in Europe
PART 14: Market drivers
Advances in insulin delivery technology
Unmet medical needs
Increase in prevalence of diabetes and obesity
Increase in awareness of diabetes
PART 15: Impact of drivers
PART 16: Market challenges
Complexity of insulin production
Poor storage condition and distribution policies
Stringent regulatory environment
Inconvenient ROA
PART 17: Impact of drivers and challenges
PART 18: Market trends
Increase in R&D for novel mechanisms
Increase in academia-industry collaborations for drug development
Increasing price of insulin drugs
Intense competition among present and upcoming vendors
PART 19: Vendor landscape
Competitive scenario
Market share analysis 2015
Sanofi
Novo Nordisk
Eli Lilly
Other prominent vendors
PART 20: Appendix
List of abbreviations
PART 21: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for insulin
Exhibit 03: History of insulin development
Exhibit 04: Incidence of diabetes among ethnic groups in US 2014
Exhibit 05: Diagnosed and undiagnosed diabetes in US by gender 2012
Exhibit 06: Diagnosed and undiagnosed diabetes in people aged 20 years or older in US 2012
Exhibit 07: Diabetes in people aged 20-79 years in Europe 2013 and 2035
Exhibit 08: Proportion of diabetes in top countries of Europe 2013 (millions)
Exhibit 09: Diabetes in Europe among people aged 20-79 years by gender 2014
Exhibit 10: Approved product portfolio
Exhibit 11: Pipeline portfolio: Insulin market in US and Europe
Exhibit 12: Share of pipeline products in insulin market in US and Europe by stage of development 2015
Exhibit 13: Pipeline share of top companies in insulin market in US and Europe
Exhibit 14: Oramed Pharmaceuticals: Pipeline products
Exhibit 15: Global insulin market 2015-2020 ($ billions)
Exhibit 16: Market share of global insulin drugs in global pharmaceutical market 2015
Exhibit 17: Global insulin market in the US and Europe 2015-2020 ($ billions)
Exhibit 18: Five forces analysis
Exhibit 19: Segmentation of insulin market in US and Europe by drug class
Exhibit 20: Market share of insulin in US and Europe by drug class
Exhibit 21: Marketed insulin formulations
Exhibit 22: Insulin market in US and Europe by application 2015
Exhibit 23: Insulin delivery technologies
Exhibit 24: Insulin pumps market in US 2015-2020 ($ millions)
Exhibit 25: Insulin pumps market in Europe 2015-2020 ($ millions)
Exhibit 26: Geographical segmentation of insulin market in US and Europe 2015
Exhibit 27: Insulin market in US 2015-2020 ($ billions)
Exhibit 28: Market share of insulin in US by drug class 2015
Exhibit 29: Insulin market in Europe 2015-2020 ($ billions)
Exhibit 30: Market share of insulin in Europe by drug class 2015
Exhibit 31: Unmet medical needs in insulin market in US and Europe
Exhibit 32: Impact of drivers
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Market share analysis 2015
Exhibit 35: Revenue share of major companies for insulin market in US and Europe 2015
Exhibit 36: Revenues from the sales of top five products in insulin market in US and Europe 2013-2015 ($ billions)
Exhibit 37: Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
Exhibit 38: Sanofi: Geographical segmentation of Lantus 2015
Exhibit 39: Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ millions)
Exhibit 40: Sanofi: Geographical segmentation of Apidra 2015
Exhibit 41: Sanofi: Geographical segmentation of Toujeo 2015
Exhibit 42: Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
Exhibit 43: Sanofi: Geographical segmentation of Insuman 2015
Exhibit 44: Sanofi: Key takeaways
Exhibit 45: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2013-2015 ($ billions)
Exhibit 46: Novo Nordisk: Geographical segmentation of revenues of NovoLog 2015
Exhibit 47: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2013-2015 ($ billions)
Exhibit 48: Novo Nordisk: Geographical segmentation of revenues of NovoMix 2015
Exhibit 49: Novo Nordisk: YoY revenue and sales growth of Levemir 2013-2015 ($ billions)
Exhibit 50: Geographical segmentation of Levemir 2015
Exhibit 51: Novo Nordisk: YoY revenue and growth rate of human insulins 2013-2015 ($ billions)
Exhibit 52: Geographical segmentation of human insulins 2015
Exhibit 53: Novo Nordisk: Key takeaways
Exhibit 54: Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
Exhibit 55: Eli Lilly: Geographical segmentation of Humalog 2015
Exhibit 56: Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
Exhibit 57: Eli Lilly: Geographical segmentation of Humalog 2015
Exhibit 58: Eli Lilly: Key takeaways